Travere Therapeutics (TVTX) Earnings Analysis
Travere Therapeutics (TVTX) has no confirmed upcoming earnings date. Last quarter (2026-05-04) it missed with EPS -0.39 USD vs -0.3 USD est (-30%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E -114.82.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does TVTX next report earnings?
No confirmed upcoming earnings date is currently scheduled for TVTX. This page updates as the calendar is published.
TVTX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-04 | -0.39 USD | -0.3 USD | -30% | Miss |
| 2026-02-19 | 0.03 USD | 0.03 USD | 0% | Beat |
| 2025-10-30 | 0.28 USD | -0.31 USD | +190.3% | Beat |
| 2025-05-01 | -0.47 USD | -0.55 USD | +14.5% | Beat |
| 2025-02-20 | -0.73 USD | -0.58 USD | -25.9% | Miss |
| 2024-10-31 | -0.7 USD | -0.7 USD | 0% | Beat |
| 2024-08-01 | -0.9 USD | -0.87 USD | -3.4% | Miss |
Beat rate: 4/7 (57%) over reported quarters with consensus data.
TVTX valuation and analyst view
| Trailing P/E | -114.82 |
|---|---|
| Trailing EPS | -0.23318 USD |
| Price / book | 52.35 |
| Dividend yield | 0.00% |
| Market cap | 5.17B |
| Analyst consensus | Buy (15 buy / 3 hold / 0 sell) |
| Avg price target | 66 USD |
Related research pages
Frequently asked questions
When is Travere Therapeutics (TVTX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for TVTX. This page updates as the calendar is published.
Did TVTX beat earnings last quarter?
In its 2026-05-04 report, TVTX posted EPS of -0.39 USD versus a -0.3 USD estimate — a miss of 30%.
What is TVTX's earnings track record?
Over the last 7 reported quarters with consensus data, TVTX beat estimates 4 times (57%).
What is TVTX's current P/E ratio and EPS?
TVTX trades at a trailing P/E of -114.82 on trailing EPS of -0.233180204191492 USD.
What do analysts rate TVTX?
Analyst consensus is "Buy" across 18 ratings (0 strong buy, 15 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 66 USD.